Traws Pharma Full Year 2023 Earnings: Beats Expectations

Simply Wall St.04-05

Traws Pharma (NASDAQ:TRAW) Full Year 2023 Results Key Financial Results Net loss: US$18.9m (flat on FY 2022). US$0.90 loss per share (improved from US$0.91 loss in FY 2022). NasdaqCM:TRAW ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2425342973?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-04-05 02:55","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2425342973","market":"us","top_or_hot":-1,"title":"Traws Pharma Full Year 2023 Earnings: Beats Expectations","media":"Simply Wall St.","content":"<div>\n<p>Traws Pharma (NASDAQ:TRAW) Full Year 2023 Results\nKey Financial Results\n\nNet loss: US$18.9m (flat on FY 2022).\nUS$0.90 loss per share (improved from US$0.91 loss in FY 2022).\n\n\n\n\n  NasdaqCM:TRAW ...</p>\n\n<a href=\"https://finance.yahoo.com/news/traws-pharma-full-2023-earnings-185551680.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Traws Pharma Full Year 2023 Earnings: Beats Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTraws Pharma Full Year 2023 Earnings: Beats Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-05 02:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/traws-pharma-full-2023-earnings-185551680.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Traws Pharma (NASDAQ:TRAW) Full Year 2023 Results\nKey Financial Results\n\nNet loss: US$18.9m (flat on FY 2022).\nUS$0.90 loss per share (improved from US$0.91 loss in FY 2022).\n\n\n\n\n  NasdaqCM:TRAW ...</p>\n\n<a href=\"https://finance.yahoo.com/news/traws-pharma-full-2023-earnings-185551680.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRAW","symbol_name":"TRAWS PHARMA","start_time":0,"source_url":"https://finance.yahoo.com/news/traws-pharma-full-2023-earnings-185551680.html","article_id":"2425342973","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2425342973","pubTimestamp":1712256951,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqCM:TRAW Revenue and Expenses Breakdown April 4th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 5.0%. Earnings per share  also surpassed analyst estimates by 5.9%.In the last 12 months, the only revenue segment was Identification and Development of Oncology Therapeutics contributing US$226.0k. The largest operating expense was Research & Development (R&D) costs, amounting to US$11.4m . Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$1.35m. Explore how TRAW's revenue and expenses shape its earnings.Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in the US.The company's shares are down 15% from a week ago.We should say that we've discovered 4 warning signs for Traws Pharma (2 can't be ignored!) that you should be aware of before investing here.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TRAW":"TRAWS PHARMA"},"translate_title":"Traws Pharma 2023年全年收益：超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONTX":0.9,"TRAW":0.9},"content_text":"Traws Pharma (NASDAQ:TRAW) Full Year 2023 Results\nKey Financial Results\n\nNet loss: US$18.9m (flat on FY 2022).\nUS$0.90 loss per share (improved from US$0.91 loss in FY 2022).\n\n\n\n\n  NasdaqCM:TRAW Revenue and Expenses Breakdown April 4th 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nTraws Pharma Revenues and Earnings Beat Expectations\n Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) also surpassed analyst estimates by 5.9%. \n In the last 12 months, the only revenue segment was Identification and Development of Oncology Therapeutics contributing US$226.0k. The largest operating expense was Research & Development (R&D) costs, amounting to US$11.4m (56% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$1.35m. Explore how TRAW's revenue and expenses shape its earnings.\n Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in the US. \nPerformance of the American Pharmaceuticals industry.\n The company's shares are down 15% from a week ago. \nRisk Analysis\n We should say that we've discovered 4 warning signs for Traws Pharma (2 can't be ignored!) that you should be aware of before investing here. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2425342973"}